NASDAQ:HSKAHeska Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heska Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $92.58 +0.74 (+0.81 %) (As of 07/13/2020 04:00 PM ET) Add Compare Share Today's Range$92.40Now: $92.58▼$94.9450-Day Range$81.10MA: $88.57▼$95.6352-Week Range$50.00Now: $92.58▼$110.90Volume101,617 shsAverage Volume75,547 shsMarket Capitalization$869.51 millionP/E RatioN/ADividend YieldN/ABeta1.72 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.Read More Beat the Market (BTM) Rank™ 1.2 Analyst's Opinion Consensus RatingHeska has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.80, Heska has a potential downside of 11.6% from its current price of $92.58.Amount of Analyst CoverageHeska has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesHeska has received 319 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHeska has received 359 “underperform” votes. (Add your “underperform” vote.)Community SentimentHeska has received 52.95% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote “Outperform” if you believe HSKA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHeska does not currently pay a dividend.Dividend GrowthHeska does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heska insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,741,842.00 in company stock.Percentage Held by InsidersOnly 11.70% of the stock of Heska is held by insiders.Percentage Held by Institutions79.67% of the stock of Heska is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heska are expected to grow in the coming year, from ($0.81) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heska is -92.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heska is -92.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeska has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.04 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HSKA Previous Symbol CUSIPN/A CIK1038133 Webwww.heska.com Phone970-493-7272Debt Debt-to-Equity Ratio0.19 Current Ratio11.21 Quick Ratio9.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$122.66 million Price / Sales7.09 Cash Flow$0.92 per share Price / Cash Flow100.48 Book Value$19.72 per share Price / Book4.69Profitability EPS (Most Recent Fiscal Year)$0.05 Net Income$-1,470,000.00 Net Margins-5.99% Return on Equity-1.04% Return on Assets-0.75%Miscellaneous Employees347 Outstanding Shares9,392,000Market Cap$869.51 million Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable NASDAQ:HSKA Rates by TradingView Receive HSKA News and Ratings via Email Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter. Heska (NASDAQ:HSKA) Frequently Asked Questions How has Heska's stock been impacted by COVID-19 (Coronavirus)? Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HSKA shares have increased by 13.1% and is now trading at $92.58. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Heska? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Heska. When is Heska's next earnings date? Heska is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Heska. How were Heska's earnings last quarter? Heska Corp (NASDAQ:HSKA) issued its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.44. The medical research company had revenue of $30.65 million for the quarter, compared to analysts' expectations of $33.47 million. Heska had a negative return on equity of 1.04% and a negative net margin of 5.99%. View Heska's earnings history. What guidance has Heska issued on next quarter's earnings? Heska issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $175-185 million, compared to the consensus revenue estimate of $150.44 million. What price target have analysts set for HSKA? 6 equities research analysts have issued 12 month price targets for Heska's stock. Their forecasts range from $59.00 to $105.00. On average, they anticipate Heska's share price to reach $81.80 in the next twelve months. This suggests that the stock has a possible downside of 11.6%. View analysts' price targets for Heska. Has Heska been receiving favorable news coverage? Media stories about HSKA stock have trended very negative on Monday, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Heska earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Heska. Who are some of Heska's key competitors? Some companies that are related to Heska include Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Myriad Genetics (MYGN), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO), Akers Biosciences (AKER) and GeneNews (GNWSF). View all competitors. What other stocks do shareholders of Heska own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Shopify (SHOP), Adobe (ADBE), Exxon Mobil (XOM), AbbVie (ABBV), Skyworks Solutions (SWKS), Alibaba Group (BABA) and Biogen (BIIB). Who are Heska's key executives? Heska's management team includes the following people: Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44) What is Heska's stock symbol? Heska trades on the NASDAQ under the ticker symbol "HSKA." Who are Heska's major shareholders? Heska's stock is owned by a number of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (3.00%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Heska stock include G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View institutional ownership trends for Heska. Which institutional investors are selling Heska stock? HSKA stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC. View insider buying and selling activity for Heska. Which institutional investors are buying Heska stock? HSKA stock was purchased by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View insider buying and selling activity for Heska. How do I buy shares of Heska? Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Heska's stock price today? One share of HSKA stock can currently be purchased for approximately $92.58. How big of a company is Heska? Heska has a market capitalization of $869.51 million and generates $122.66 million in revenue each year. The medical research company earns $-1,470,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Heska employs 347 workers across the globe. What is Heska's official website? The official website for Heska is www.heska.com. How can I contact Heska? Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected] This page was last updated on 7/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
